Tvilsom dokumentasjon av effekten av pregabalin ved fibromyalgi

Tidsskrift for den Norske Laegeforening

Volumn 130, Issue 10, 2010, Pages 1032-1036

  Holtedahl, Robin ^a  

^a Avdeling for fysikalsk medisin og rehabilitering Sykehuset   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DRUG DERIVATIVE; PREGABALIN;

CONFLICT OF INTEREST; DOCUMENTATION; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; FIBROMYALGIA; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANALGESICS; CONFLICT OF INTEREST; DOCUMENTATION; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77953639211     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.0576     Document Type: Review

References (42)

1. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 2007; 335: 1202-5.
2. Bekelman JE, Li Y, Gross CP. Scope and Impact of financial conflicts of interest in biomedical research. A systematic review. JAMA 2003; 289: 454-65.
3. Angell M. Relationships with the drug industry: Keep at arm's length. BMJ 2009; 338: b222.
4. Landefeld CS, Steinman MA. The Neurontin legacy - marketing through misinformation and manipulation. N Engl J Med 2009; 360: 103-6.
5. Steinman MA, Bero LA, Chren MM et al. Narrative review: The promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006; 145: 284-293.
6. Vedula SS, Bero L, Scherer RW et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009; 361: 1963-71.
7. Dooley DJ, Taylor CP, Donevan S et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28: 75-82.
8. Pfizer profit beats forecasts. www.reuters.com/article/idUSTRE53R2LU20090428 (9.12.2009).
9. Chalabianloo F, Schjøtt F. Pregabalin og misbrukspotensial. Tidsskr Nor Legeforen 2009; 129: 186-7.
10. Moore RA, Straube S, Wiffen PJ et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; nr 3: CD007076.
11. Wu SC, Wrobel JS, Armstrong DG. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. Pain Med 2007; 8 (suppl 2): 33-42.
12. Forseth KO, Gran JT. Fibromyalgi og medikamentell behandling. Tidsskr Nor Lægeforen 2006; 126: 1486-7.
13. Anderberg UM, Horwitz EB. Fibromyalgi - årsaker og behandling. Oslo: Cappelen Damm, 2008.
14. Crofford LJ, Rowbotham MC, Mease PJ et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-73.
15. Lawson K. Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies? Drug Discov Today 2008; 13: 333-40.
16. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol 2008; 20: 246-50.
17. Perrot S. Fibromyalgia syndrome: a relevant recent construction of an ancient condition? Curr Opin Support Palliat Care 2008; 2: 122-7.
18. Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008; 8: 177-89.
19. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 2007; 21: 499-511.
20. Abeles M, Solitar BM, Pillinger MH et al. Update on fibromyalgia therapy. Am J Med 2008; 121: 555-61.
21. Abeles M, Abeles AM. Is pregabalin better than conventional therapy in fibromyalgia? Arthritis Rheum 2008; 58 (suppl): 396.
22. Farrar JT, Young JP jr., LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-58.
23. Mease PJ, Russell IJ, Arnold LM et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008; 35: 502-14.
24. Arnold LM, Russell IJ, Diri EW et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008; 9: 792-805.
25. Pauer L, Danneskiold-Samsø B, Jespersen A et al. Pregabalin for management of fibromyalgia: a 14-week, randomized, double-blind, placebocontrolled, monotherapy trial. Ann Rheum Dis 2008; 67 (suppl 2): 256.
26. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat 2008; 4: 1059-71.
27. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. Drugs 2008; 68: 2205-23.
28. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67: 536-41.
29. Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007; 19: 111-7.
30. Kim L, Lipton S, Deodhar A. Pregabalin for fibromyalgia: some relief but no cure. Cleve Clin J Med 2009; 76: 255-61.
31. Buskila D. Developments in the scientific and clinical understanding of fibromyalgia. Arthritis Res Ther 2009; 11: 242.
32. Chong YY, Ng BY. Clinical aspects and management of fibromyalgia syndrome. Ann Acad Med Singapore 2009; 38: 967-7.
33. Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr Dis Treat 2008; 4: 1193-201.
34. Sumpton JE, Moulin DE. Fibromyalgia: presentation and management with a focus on pharmacological treatment. Pain Res Manag 2008; 13: 477-83.
35. Lyrica pregabalin. www.lyrica.com/fibro_homepage.aspx (3.12.2009).
36. Kurtze N, Gundersen KT, Svebak S. The role of anxiety and depression in fatigue and patterns of pain among subgroups of fibromyalgia patients. Br J Med Psychol 1998; 71: 185-94.
37. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 2007; 64: 1475-82.
38. Thieme K, Flor H, Turk DC. Psychological pain treatment in fibromyalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments. Arthritis Res Ther 2006; 8: R121.
39. Knardahl S. Kropp og sjel. Psykologi, biologi og helse. Oslo: Universitetsforlaget, 1998.
40. European Medicines Agency (EMEA). Scientific discussion. London, 20 March 2005. Product name: LYRICA. Product no: EMEA/H/C/000546/II/ 0004. www.emea.europa.eu/humandocs/PDFs/EPAR/lyrica/Lyrica%20H-546-II-04-AR.pdf (22.02.2010).
41. Pfizer Settlement Agreement. www.justice.gov/05publications/resources.html (10.12.2009).
42. Bretthauer M, Haug C. Uten registrering, ingen publisering! Tidsskr Nor Legeforen 2009; 129: 733.